A Case of Severe Chronic Heart Failure Successfully Controlled with Long Term Administration of Tolvaptan; a V(2)-specific Vasopressin Receptor Antagonists

被引：0
|
作者：
Yamagami, Yuna [1 ]
Kinoshita, Hideyuki [1 ]
Kuwahara, Koichiro [1 ]
Kuwabara, Yoshihiro [1 ]
Yasuno, Shinji [2 ]
Usami, Satoru [1 ]
Nakagawa, Yasuaki [1 ]
Nishikimi, Toshio [1 ]
Ueshima, Kenji [2 ]
Nakao, Kazuwa [1 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Kyoto, Japan
[2] Kyoto Univ, EBM Res Ctr, Kyoto, Japan
来源：
JOURNAL OF CARDIAC FAILURE | 2011年 / 17卷 / 09期
关键词：
D O I：
10.1016/j.cardfail.2011.06.565
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S166 / S166
页数：1
相关论文
共 50 条
  • [21] Vasopressin-V2-Receptor Antagonism (Tolvaptan) as a Potential Treatment for Right Sided Heart Failure Refractory to Standard Therapy
    Takagi, Atsutoshi
    Miyauti, Katsumi
    Suda, Syouko
    Miyazaki, Tetsurou
    Daita, Hiroyuki
    JOURNAL OF CARDIAC FAILURE, 2012, 18 (10) : S162 - S162
  • [22] Renoprotective Effect of Vasopressin V2 Receptor Antagonist Tolvaptan in Dahl Rats With End-Stage Heart Failure
    Ishikawa, Mayuko
    Kobayashi, Naohiko
    Sugiyama, Fumihiro
    Onoda, Sho
    Ishimitsu, Toshihiko
    INTERNATIONAL HEART JOURNAL, 2013, 54 (02) : 98 - 106
  • [23] Short-term Outcomes of 26 Patients of Severe Chronic Heart Failure Treated with Tolvaptan
    Ogawa, Hayato
    Murase, Yosuke
    Nakano, Yoshihisa
    Hara, Akitoshi
    Fujikawa, Yuusuke
    Osanai, Hiroyuki
    Nakashima, Yoshihito
    Asano, Hiroshi
    Ajioka, Masayoshi
    Sakai, Kazuyoshi
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (09) : S151 - S151
  • [24] Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure
    Kazuhiro Nakao
    Takeshi Horio
    Ryutaro Yoshimura
    Ryosuke Fujiwara
    Yujiro Matsuoka
    Go Yokouchi
    Haruo Nakamura
    Yuya Sakamoto
    Kohei Fujimoto
    Yasuhiro Izumiya
    Minoru Yoshiyama
    Noriaki Kasayuki
    Heart and Vessels, 2021, 36 : 1175 - 1182
  • [25] Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: A randomized, double-blind trial
    Gheorghiade, M
    Niazi, I
    Ouyang, J
    Czerwiec, F
    Kambayashi, JI
    Orlandi, C
    CIRCULATION, 2000, 102 (18) : 592 - +
  • [26] Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia
    Miyazaki, T
    Yamamura, Y
    Onogawa, T
    Nakamura, S
    Kinoshita, S
    Nakayama, S
    Fujiki, H
    Mori, T
    ENDOCRINOLOGY, 2005, 146 (07) : 3037 - 3043
  • [27] Long-term Effect of Tolvaptan in "Super-aged" Patients with Chronic Heart Failure
    Koyama, Toru
    JOURNAL OF CARDIAC FAILURE, 2013, 19 (10) : S159 - S160
  • [28] Vasopressin V2 Receptor Antagonist Tolvaptan Prevents The Development of Chronic Heart Failure via Its Anti-inflammatory and Anti-fibrotic Actions
    Yamazaki, Takanori
    Izumi, Yasukatsu
    Nakamura, Yasuhiro
    Yamaguchi, Takehiro
    Hanatani, Akihisa
    Shimada, Kenei
    Iwao, Hiroshi
    Yoshiyama, Minoru
    CIRCULATION, 2012, 126 (21)
  • [29] Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats
    Nishikimi, T
    Kawano, Y
    Saito, Y
    Matsuoka, H
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (02) : 275 - 282
  • [30] Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure
    Yamashita, Shoko
    Takenaka, Miki
    Ohbayashi, Masayuki
    Kohyama, Noriko
    Kurihara, Tatsuya
    Sunaga, Tomiko
    Ishiguro, Hisaaki
    Kogo, Mari
    SINGAPORE MEDICAL JOURNAL, 2024, 65 (11) : 614 - 623
12345